MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
March 3-6, 2024 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Stefano Romeo, Michael Charlton, Silvia C. Sookoian and Gregory Tesz
In Person
On Demand
March 3-6, 2024 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Stefano Romeo, Michael Charlton, Silvia C. Sookoian and Gregory Tesz
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Booking Function
Fundraising
Sunday, March 3, 2024
Arrival and Registration
4:00–8:00 PM
Riverview Lounge
Welcome Mixer
6:00–8:00 PM
Riverview Lounge
Monday, March 4, 2024
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
Welcome and Keynote Address
8:00–9:00 AM
Cascade Ballroom
Arun J. Sanyal, Virginia Commonwealth University Medical Center
MASH and Fibrosis: What have we Learned from Clinical Trials?
MASH and Fibrosis: What have we Learned from Clinical Trials?
The Origin of the Nile: What is the Culprit of MASH?
9:00–11:15 AM
Cascade Ballroom
Mohammed Eslam, University of Sydney
Nutritional, Non-Alcoholic or Metabolic associated Fatty Liver Disease?
Nutritional, Non-Alcoholic or Metabolic associated Fatty Liver Disease?
Amalia Gastaldelli, Institute of Clinical Physiology
Worsening of Metabolic Fluxes: From Hepatic Steatosis to MASH
Worsening of Metabolic Fluxes: From Hepatic Steatosis to MASH
Silvia C. Sookoian, CONICET. Universidad Maimonides
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
Coffee Break
9:30–9:50 AM
Riverview Lounge
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Alberta/New Brunswick
Poster Viewing
1:00–10:00 PM
Alberta/New Brunswick
Workshop 1: Inflammation and Fibrosis: Novel Disease Mechanisms
2:30–4:30 PM
Cascade Ballroom
KUO DU, Duke Universty
Aging Promotes Metabolic Dysfunction-associated Steatotic Liver Disease by Inducing Ferroptotic Stress in Hepatocytes
Aging Promotes Metabolic Dysfunction-associated Steatotic Liver Disease by Inducing Ferroptotic Stress in Hepatocytes
Celine Hoffmann, CNRS
Characterization and Purification of Hypertrophied Hepatic Stellate Cells and their Association with Liver Fibrosis
Characterization and Purification of Hypertrophied Hepatic Stellate Cells and their Association with Liver Fibrosis
Xin (Tony) Tong, University of Michigan Medical School
Activation of Hepatocyte E4BP4-OPN Axis Promotes Liver Fibrosis in Non-alcoholic Steatohepatitis
Activation of Hepatocyte E4BP4-OPN Axis Promotes Liver Fibrosis in Non-alcoholic Steatohepatitis
Clémence Schmitt, University of Montreal / IRCM
Glucolipotoxicity Regulates the Secretion of Interleukin-6 Trans-Signaling Inhibitor, sgp130, Through Matrix Metalloproteases Shedding in Hepatic Stellate Cells
Glucolipotoxicity Regulates the Secretion of Interleukin-6 Trans-Signaling Inhibitor, sgp130, Through Matrix Metalloproteases Shedding in Hepatic Stellate Cells
Kathryn Buscher, University of Michigan
Glucose-mediated Control of STAT3 Activation in Fibrosis
Glucose-mediated Control of STAT3 Activation in Fibrosis
William De Nardo, University of Melbourne
Targeting the Endocrine Actions of a MASH-inducible Hepatic Stellate Cell Secreted Protein – a Worthwhile Venture
Targeting the Endocrine Actions of a MASH-inducible Hepatic Stellate Cell Secreted Protein – a Worthwhile Venture
Tima Dehghani, insitro
Interrogating the Effect of Fibrosis on Hepatocyte Transcriptome and Lipid Accumulation Phenotype
Interrogating the Effect of Fibrosis on Hepatocyte Transcriptome and Lipid Accumulation Phenotype
Coffee Available
4:30–5:00 PM
Riverview Lounge
Steatotic Liver Disease: Multiple Phenotypes or Different Diseases?
5:00–7:00 PM
Cascade Ballroom
Vincent WS Wong, Chinese University of Hong Kong
Lean NAFLD: Molecular Mechanisms of MASH and Fibrosis
Lean NAFLD: Molecular Mechanisms of MASH and Fibrosis
Julia Kozlitina, University of Texas Southwestern Medical Center
Molecular Basis of Ethnic Differences in MASH and Fibrosis
Molecular Basis of Ethnic Differences in MASH and Fibrosis
Päivi Pajukanta, David Geffen School of Medicine at UCLA
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics
Lewis R. Roberts, Mayo Clinic
Cirrhotic and Noncirrhotic: Mechanisms of Hepatocellular Carcinoma in SLD
Cirrhotic and Noncirrhotic: Mechanisms of Hepatocellular Carcinoma in SLD
Federica Tavaglione, Università Campus Bio-Medico di Roma
Short Talk: A Data-Driven Cluster Analysis Identifies Distinct Types of Metabolic Dysfunction-Associated Steatotic Liver Disease
Short Talk: A Data-Driven Cluster Analysis Identifies Distinct Types of Metabolic Dysfunction-Associated Steatotic Liver Disease
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Poster Session 1
7:30–10:00 PM
Alberta/New Brunswick
Tuesday, March 5, 2024
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
Preclinical Model of MASH Clinical Trials
8:00–11:00 AM
Cascade Ballroom
Peter Olinga, University of Groningen
Precision Slice Cut as a Preclinical Model of MASH
Precision Slice Cut as a Preclinical Model of MASH
Jennifer L. Estall, Institut de Recherches Cliniques de Montréal
Modeling MASH in Mice: Overcoming Problems in Translation
Modeling MASH in Mice: Overcoming Problems in Translation
Elia Casirati, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Short Talk: PNPLA3 p.I148M Variant Affects Lipid Droplets Number and Size in Patient-derived Liver Organoids
Short Talk: PNPLA3 p.I148M Variant Affects Lipid Droplets Number and Size in Patient-derived Liver Organoids
Marcel den Hoed, Uppsala University
Short Talk: Characterizing 99 Cardiometabolic Candidate Genes for a Role in MASLD Using CRISPR/Cas9, in vivo Imaging and Deep Learning in Zebrafish Larvae
Short Talk: Characterizing 99 Cardiometabolic Candidate Genes for a Role in MASLD Using CRISPR/Cas9, in vivo Imaging and Deep Learning in Zebrafish Larvae
Francesca M Lazzeri-Barcelo, Karolinska Institutet
Short Talk: Non-Invasive in vivo Imaging of Liver Spheroids Engrafted in the Anterior Chamber of the Eye
Short Talk: Non-Invasive in vivo Imaging of Liver Spheroids Engrafted in the Anterior Chamber of the Eye
Scott Heyward, BioIVT
Short Talk: Using siRNA Generated Isogenic Pairs in a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC) to Define the Role of CIDEB in a Model of Hepatic Steatosis
Short Talk: Using siRNA Generated Isogenic Pairs in a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC) to Define the Role of CIDEB in a Model of Hepatic Steatosis
Coffee Break
9:00–9:20 AM
Riverview Lounge
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Alberta/New Brunswick
Poster Viewing
1:00–10:00 PM
Alberta/New Brunswick
Career Roundtable
3:00–4:30 PM
Cascade Ballroom
Lewis R. Roberts, Mayo Clinic
Professor
Professor
Bani Mukhopadhyay, National Institutes of Health
Staff Scientist
Staff Scientist
Coffee Available
4:30–5:00 PM
Riverview Lounge
Current Status and Future of Endpoints to Assess Efficacy in Clinical Trials
5:00–7:00 PM
Cascade Ballroom
Alina M. Allen, Mayo Clinic
Identifying Populations at Risk for Liver Events – is MASH with Fibrosis by Histology the only Way?
Identifying Populations at Risk for Liver Events – is MASH with Fibrosis by Histology the only Way?
Michael Charlton, University of Chicago Medicine
Is Regression of Fibrosis the Only Surrogate for Outcomes Benefit?
Is Regression of Fibrosis the Only Surrogate for Outcomes Benefit?
Manal F. Abdelmalek, Mayo Clinic
Assessing Response to Drug Treatment Beyond Liver Biopsy
Assessing Response to Drug Treatment Beyond Liver Biopsy
Francois Pattou, Lille University
Short Talk: Resolution of MASH with No Worsening of Fibrosis after Bariatric Surgery Improves 15-year Survival
Short Talk: Resolution of MASH with No Worsening of Fibrosis after Bariatric Surgery Improves 15-year Survival
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Poster Session 2
7:30–10:00 PM
Alberta/New Brunswick
Wednesday, March 6, 2024
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
Genetic Insights into MASH, Fibrosis and Hepatocellular Carcinoma
8:00–11:00 AM
Cascade Ballroom
Stefano Romeo, University of Gothenburg
Human Genetics of Steatotic Liver Disease: What Have We Learned So Far?
Human Genetics of Steatotic Liver Disease: What Have We Learned So Far?
Luca Vittorio C Valenti, University of Milan
PNPLA3, Estrogens and SLD Progression in Women
PNPLA3, Estrogens and SLD Progression in Women
Luca Lotta, Regeneron Pharmaceuticals Inc.
Human Genetics of Liver Disease and Implications for Therapeutic Development
Human Genetics of Liver Disease and Implications for Therapeutic Development
Eleonora Scorletti, University of Pennsylvania
Short Talk: Association of a Glucagon-like Peptide-1 Receptor Gene Variant with Metabolic Dysfunction Associated Liver Disease (MASLD)
Short Talk: Association of a Glucagon-like Peptide-1 Receptor Gene Variant with Metabolic Dysfunction Associated Liver Disease (MASLD)
Ype de Jong, Weill Cornell Medicine
Short Talk: Overexpressing PNPLA3-148I or ABHD5 Differentially Protects Primary Human Hepatocytes from Hypercaloric Diet-induced Steatosis Depending on their PNPLA3 Genotype
Short Talk: Overexpressing PNPLA3-148I or ABHD5 Differentially Protects Primary Human Hepatocytes from Hypercaloric Diet-induced Steatosis Depending on their PNPLA3 Genotype
Allison Wing, National Institutes of Health
Short Talk: Hsd17b13 Loss Adversely Impacts Glucose-insulin Metabolism
Short Talk: Hsd17b13 Loss Adversely Impacts Glucose-insulin Metabolism
Justin Crane, Pfizer
Short Talk: Murine HSD17B13 Does Not Control Liver Steatosis and Modestly Impacts Fibrosis Under Specific Dietary Conditions
Short Talk: Murine HSD17B13 Does Not Control Liver Steatosis and Modestly Impacts Fibrosis Under Specific Dietary Conditions
Coffee Break
9:00–9:20 AM
Riverview Lounge
On Own for Lunch
11:00–5:00 PM
Workshop 2: Therapeutics: Novel Drug Candidates
2:30–4:30 PM
Cascade Ballroom
Haressh Sajiir, Mater Research Institute - The University of Queensland
Development of Liver-targeted Interleukin-22 for Metabolic Dysfunction Associated Steatohepatitis
Development of Liver-targeted Interleukin-22 for Metabolic Dysfunction Associated Steatohepatitis
Erik J. Tillman, Akero Therapeutics
Efruxifermin Significantly Improved Collagen Biomarkers Consistent with Beneficial ECM Remodeling in Patients with F2-F3 Fibrosis Due to MASH
Efruxifermin Significantly Improved Collagen Biomarkers Consistent with Beneficial ECM Remodeling in Patients with F2-F3 Fibrosis Due to MASH
Yaron Rotman, NIDDK, National Institutes of Health
The Postprandial Plasma Proteome is Altered in People with Metabolic Dysfunction-associated Steatotic Liver Disease
The Postprandial Plasma Proteome is Altered in People with Metabolic Dysfunction-associated Steatotic Liver Disease
Reza Zarnegar, University of Pittsburgh, School of Medicine
A Novel Humanized Model of NASH and its Treatment with META4 a Potent Agonist of MET
A Novel Humanized Model of NASH and its Treatment with META4 a Potent Agonist of MET
Brenna Pearson-Gallion, Louisiana State University Health Sciences Shreveport
EphA2 Promotes Inflammation and Alters Hepatocyte Metabolism to Enhance Metabolic Dysfunction-associated Steatotic Liver Disease
EphA2 Promotes Inflammation and Alters Hepatocyte Metabolism to Enhance Metabolic Dysfunction-associated Steatotic Liver Disease
Christy M Gliniak, University of Texas Southwestern Medical Center
Methionine Aminopeptidase 2 (MetAP2) Regulates Anabolic and Catabolic Metabolism in Hepatocytes Through Ancient Mechanisms That Control Protein Translation
Methionine Aminopeptidase 2 (MetAP2) Regulates Anabolic and Catabolic Metabolism in Hepatocytes Through Ancient Mechanisms That Control Protein Translation
Matti Hoch, University of Rostock
Investigating MASLD Using a Multi-level Computational Model
Investigating MASLD Using a Multi-level Computational Model
Yuanyuan Qin, UCSF
TMEM55B deficiency alters lysosomal fatty acid trafficking and induces metabolic dysfunction associated steatohepatitis (MASH)
TMEM55B deficiency alters lysosomal fatty acid trafficking and induces metabolic dysfunction associated steatohepatitis (MASH)
Coffee Available
4:30–5:00 PM
Riverview Lounge
Opportunities and Challenges of Precision Medicine in Steatotic Liver Disease
5:00–6:45 PM
Cascade Ballroom
Heather Hsu, Inipharm
HSD17B13 Inhibition with INI-822 Phenocopies the Human HSD17B13 Protective Allele
HSD17B13 Inhibition with INI-822 Phenocopies the Human HSD17B13 Protective Allele
Gregory Tesz, Pfizer
Targeting PNPLA3 148M to Treat MASH and Fibrosis
Targeting PNPLA3 148M to Treat MASH and Fibrosis
Shuang Wang, Icahn School of Medicine at Mount Sinai
Hepatic Stellate Cell Plasticity and Maladaptive Fibrogenic Memory in CLD
Hepatic Stellate Cell Plasticity and Maladaptive Fibrogenic Memory in CLD
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Cascade Ballroom
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Alberta/New Brunswick
Thursday, March 7, 2024
Departure
7:00–11:59 PM
Subscribe for Updates